AR105393A1 - Composiciones adyuvantes liposómicas - Google Patents
Composiciones adyuvantes liposómicasInfo
- Publication number
- AR105393A1 AR105393A1 ARP160102185A ARP160102185A AR105393A1 AR 105393 A1 AR105393 A1 AR 105393A1 AR P160102185 A ARP160102185 A AR P160102185A AR P160102185 A ARP160102185 A AR P160102185A AR 105393 A1 AR105393 A1 AR 105393A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccine composition
- carbon atoms
- independently hydrogen
- alkyl radical
- saturated
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 9
- -1 La-aminobutyl Chemical group 0.000 abstract 18
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 229960005486 vaccine Drugs 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract 3
- 229930186217 Glycolipid Natural products 0.000 abstract 3
- 229930182558 Sterol Natural products 0.000 abstract 3
- 239000002502 liposome Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 150000003856 quaternary ammonium compounds Chemical class 0.000 abstract 3
- 150000003432 sterols Chemical class 0.000 abstract 3
- 235000003702 sterols Nutrition 0.000 abstract 3
- 241000283690 Bos taurus Species 0.000 abstract 2
- 241000223924 Eimeria Species 0.000 abstract 2
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 abstract 2
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 abstract 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 abstract 2
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 abstract 2
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 abstract 2
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 abstract 2
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 abstract 2
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 abstract 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 abstract 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 abstract 2
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 abstract 2
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 abstract 2
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- 229920006395 saturated elastomer Chemical group 0.000 abstract 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 abstract 1
- 239000000232 Lipid Bilayer Substances 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000003125 aqueous solvent Substances 0.000 abstract 1
- PPBOKXIGFIBOGK-BDTUAEFFSA-N bvdv Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 abstract 1
- 210000003250 oocyst Anatomy 0.000 abstract 1
- 244000144977 poultry Species 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 241000114864 ssRNA viruses Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Un liposoma caracterizado porque comprende una membrana de bicapa lipídica externa y un compartimento interno, en donde la membrana externa comprende: a) un compuesto de amonio cuaternario; b) un esterol; c) un fosfolípido; y d) un glucolípido de la fórmula (1) en donde R¹ y R² son independientemente hidrógeno o un radical alquilo saturado que tiene hasta 20 átomos de carbono; X es -CH₂-, -O- o -NH-; R² es hidrógeno o un radical alquilo saturado o insaturado que tiene hasta 20 átomos de carbono; R³, R⁴ y R⁵ son independientemente hidrógeno, -SO₄²⁻, -PO₄²⁻, -COC₁₋₁₀ alquilo; R⁶ es L-alanilo, L-a-aminobutilo, L-arginilo, L-asparginilo, L-aspartilo, L-cisteinilo, L-glutamilo, L-glicilo, L-histidilo, L-hidroxiprolilo, L-isoleucilo, L-leucilo, L-lisilo, L-metionilo, L-ornitinilo, L-fenialani, L-prolilo, L-serilo, L-treonilo, L-tirosilo, L-triptofanilo y L-valilo o sus D-isómeros. Reivindicación 3: El liposoma de acuerdo con las reivindicaciones 1 ó 2, caracterizado porque el compuesto de amonio cuaternario es DDA, el esterol es colesterol, y el glucolípido es N-(2-desoxi-2-L-leucilamino-b-D-glucopiranosil)-N-octadecildodecanoilamida o una sal de este. Reivindicación 8: Una composición vacunal caracterizada porque comprende una cantidad eficaz de un componente antigénico y la formulación adyuvante de acuerdo con la reivindicación 6 o la reivindicación 7. Reivindicación 14: Un método para inducir una respuesta inmunitaria contra BVDV en un animal bovino caracterizado porque comprende administrar al animal bovino la composición vacunal de acuerdo con la reivindicación 13. Reivindicación 18: Un método para prevenir la propagación de ooquistes de Eimeria en un ave de corral infectado con Eimeria, caracterizado porque comprende administrar a dicho animal la composición vacunal de acuerdo con la reivindicación 18 antes de la infección. Reivindicación 19: La composición vacunal de acuerdo con la reivindicación 11, caracterizado porque el componente antigénico comprende un virus ssARN, y en donde la composición vacunal es sustancialmente libre de oligodesoxirribonucleótido CpG. Reivindicación 22: Un método para preparar el liposoma de acuerdo con la reivindicación 1, caracterizado porque comprende: a) disolver en un solvente orgánico el compuesto de amonio cuaternario, el esterol, el fosfolípido y el glucolípido de la fórmula (1), en donde R¹ y R² son independientemente hidrógeno o un radical alquilo saturado que tiene hasta 20 átomos de carbono; X es -CH₂-, -O- o -NH-; R² es hidrógeno o un radical alquilo saturado o insaturado que tiene hasta 20 átomos de carbono; R³, R⁴ y R⁵ son independientemente hidrógeno, -SO₄²⁻, -PO₄²⁻, -COC₁₋₁₀ alquilo; R⁶ es L-alanilo, L-a-aminobutilo, L-arginilo, L-asparginilo, L-aspartilo, L-cisteinilo, L-glutamilo, L-glicilo, L-histidilo, L-hidroxiprolilo, L-isoleucilo, L-leucilo, L-lisilo, L-metionilo, L-ornitinilo, L-fenialani, L-prolilo, L-serilo, L-treonilo, L-tirosilo, L-triptofanilo y L-valilo o sus D- isómeros; b) retirar el solvente orgánico y formar una película; c) rehidratar la película en un solvente acuoso, y así formar una composición rehidratada; d) microfluidizar la composición rehidratada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562194355P | 2015-07-20 | 2015-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105393A1 true AR105393A1 (es) | 2017-09-27 |
Family
ID=56555804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102185A AR105393A1 (es) | 2015-07-20 | 2016-07-19 | Composiciones adyuvantes liposómicas |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP3325015B1 (es) |
| JP (1) | JP6975132B2 (es) |
| KR (1) | KR102085968B1 (es) |
| CN (1) | CN107847603B (es) |
| AR (1) | AR105393A1 (es) |
| AU (1) | AU2016297529B2 (es) |
| BR (1) | BR112018001318B1 (es) |
| CA (1) | CA2992892C (es) |
| CL (1) | CL2018000155A1 (es) |
| CO (1) | CO2018000496A2 (es) |
| CY (1) | CY1124319T1 (es) |
| DK (1) | DK3325015T3 (es) |
| ES (1) | ES2878475T3 (es) |
| HK (1) | HK1250338A1 (es) |
| HR (1) | HRP20210872T1 (es) |
| HU (1) | HUE054422T2 (es) |
| LT (1) | LT3325015T (es) |
| MX (1) | MX2018000879A (es) |
| PH (1) | PH12018500146A1 (es) |
| PL (1) | PL3325015T3 (es) |
| PT (1) | PT3325015T (es) |
| RS (1) | RS62015B1 (es) |
| RU (1) | RU2736642C2 (es) |
| SI (1) | SI3325015T1 (es) |
| TW (1) | TWI655002B (es) |
| UA (1) | UA125017C2 (es) |
| WO (1) | WO2017015252A1 (es) |
| ZA (1) | ZA201800285B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202206098A (zh) * | 2020-08-11 | 2022-02-16 | 美商碩騰服務公司 | 抗冠狀病毒疫苗 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3521994A1 (de) * | 1985-06-20 | 1987-01-02 | Bayer Ag | N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| US5556637A (en) * | 1990-08-06 | 1996-09-17 | A. Nattermann & Cie. Gmbh | Water containing liposome system |
| AU750379B2 (en) * | 1997-04-30 | 2002-07-18 | Merieux Oravax | Anti-helicobacter vaccine composition comprising a Th1 adjuvant |
| US8088388B2 (en) * | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| EP1547581A1 (en) * | 2003-12-23 | 2005-06-29 | Vectron Therapeutics AG | Liposomal vaccine for the treatment of human hematological malignancies |
| BRPI0512757B8 (pt) * | 2004-07-07 | 2021-05-25 | Statens Seruminstitut | método de estabilização de lipossomos catiônicos em formulações aquosas, produto de lipossomo, adjuvante de vacina, vacina contra clamídia, malária ou tuberculose e sistema de distribuição |
| US7749520B2 (en) * | 2004-07-07 | 2010-07-06 | Statens Serum Institut | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids |
| MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| ES2425576T3 (es) * | 2006-01-26 | 2013-10-16 | Zoetis P Llc | Composiciones coadyuvantes glucolipídicas novedosas |
| JP5659332B2 (ja) * | 2008-06-27 | 2015-01-28 | ゾエティス・エルエルシー | 新規なアジュバント組成物 |
| MX340830B (es) | 2009-04-30 | 2016-07-26 | Coley Pharm Group Inc | Vacuna neumococica y usos de la misma. |
| SG178447A1 (en) * | 2009-09-03 | 2012-03-29 | Pfizer Vaccines Llc | Pcsk9 vaccine |
| AU2011259718B2 (en) * | 2010-05-28 | 2016-03-03 | Zoetis Belgium S.A. | Vaccines comprising cholesterol and CpG as sole adjuvant - carrier molecules |
| US20140112979A1 (en) * | 2011-07-04 | 2014-04-24 | Statens Serum Institut | Methods for producing liposomes |
| CN102973506B (zh) * | 2011-09-05 | 2015-06-03 | 中国科学院深圳先进技术研究院 | 阳离子脂质体及其制备方法 |
| JP6505084B2 (ja) * | 2013-05-14 | 2019-04-24 | ゾエティス・サービシーズ・エルエルシー | 免疫刺激性オリゴヌクレオチドを含む新規のワクチン組成物 |
| CA2924526A1 (en) * | 2013-09-19 | 2015-03-26 | Paul Joseph Dominowski | Water-in-oil emulsions comprising immunostimulatory oligonucleotides |
| FR3012964A1 (fr) * | 2013-11-12 | 2015-05-15 | Seppic Sa | Vaccins adjuves pour vaccination aviaire in ovo |
-
2016
- 2016-07-19 TW TW105122775A patent/TWI655002B/zh active
- 2016-07-19 WO PCT/US2016/042882 patent/WO2017015252A1/en active Application Filing
- 2016-07-19 LT LTEP16745318.2T patent/LT3325015T/lt unknown
- 2016-07-19 HU HUE16745318A patent/HUE054422T2/hu unknown
- 2016-07-19 PL PL16745318T patent/PL3325015T3/pl unknown
- 2016-07-19 BR BR112018001318-8A patent/BR112018001318B1/pt active IP Right Grant
- 2016-07-19 RS RS20210785A patent/RS62015B1/sr unknown
- 2016-07-19 CN CN201680042420.3A patent/CN107847603B/zh active Active
- 2016-07-19 PT PT167453182T patent/PT3325015T/pt unknown
- 2016-07-19 KR KR1020187004751A patent/KR102085968B1/ko active IP Right Grant
- 2016-07-19 MX MX2018000879A patent/MX2018000879A/es unknown
- 2016-07-19 CA CA2992892A patent/CA2992892C/en active Active
- 2016-07-19 AU AU2016297529A patent/AU2016297529B2/en active Active
- 2016-07-19 JP JP2018502803A patent/JP6975132B2/ja active Active
- 2016-07-19 RU RU2018102114A patent/RU2736642C2/ru active
- 2016-07-19 DK DK16745318.2T patent/DK3325015T3/da active
- 2016-07-19 ES ES16745318T patent/ES2878475T3/es active Active
- 2016-07-19 UA UAA201800567A patent/UA125017C2/uk unknown
- 2016-07-19 AR ARP160102185A patent/AR105393A1/es unknown
- 2016-07-19 EP EP16745318.2A patent/EP3325015B1/en active Active
- 2016-07-19 SI SI201631259T patent/SI3325015T1/sl unknown
-
2018
- 2018-01-16 ZA ZA2018/00285A patent/ZA201800285B/en unknown
- 2018-01-18 PH PH12018500146A patent/PH12018500146A1/en unknown
- 2018-01-19 CL CL2018000155A patent/CL2018000155A1/es unknown
- 2018-01-19 CO CONC2018/0000496A patent/CO2018000496A2/es unknown
- 2018-07-27 HK HK18109762.7A patent/HK1250338A1/zh unknown
-
2021
- 2021-06-01 HR HRP20210872TT patent/HRP20210872T1/hr unknown
- 2021-07-14 CY CY20211100637T patent/CY1124319T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016109925A (ru) | Адъюванты на масляной основе | |
| AR059192A1 (es) | Composiciones coadyuvantes glicolipidicas | |
| PE20060291A1 (es) | Composiciones farmaceuticas inyectables de posaconazol con particulas estabilizadas | |
| CO6251369A2 (es) | Vacuna de influenza de emulsion de aceite en agua | |
| HRP20141122T1 (hr) | Cjepivo protiv influence | |
| CO6220906A2 (es) | Surfactantes de alquilamidopropil dialquilamina como adyuvantes | |
| EA202090495A1 (ru) | Производные 6-амино-7,9-дигидро-8h-пурин-8-она в качестве иммуностимулирующих агонистов toll-подобного рецептора 7 (tlr7) | |
| US10561632B1 (en) | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms | |
| UA107658C2 (en) | Compatibilized electrolyte formulations | |
| CO6251273A2 (es) | Composiciones para vacuna en emulsion que comprenden antigeno y un adyuvante en la fase acuosa y su metodo de elaboracion | |
| KR20200098476A (ko) | 트리테르펜 사포닌 유사체 | |
| BR112018067927A2 (pt) | formulação, método de tratamento de plantas, método agrícola e kit | |
| ES2227698T3 (es) | Formulacion de lipidos inmunoestimuladores. | |
| BR112013018074A2 (pt) | métodos para a preparação de vesículas e formulações produzidas a partir dessas | |
| AR105393A1 (es) | Composiciones adyuvantes liposómicas | |
| RU2014119858A (ru) | Применение мелатонина для лечения и/или предотвращения мукозита | |
| AR123110A1 (es) | Vacunas anticoronavirus | |
| RU2016111704A (ru) | Производные дезоксинойиримицина и способы их применения | |
| WO2008093772A1 (ja) | 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤 | |
| US20230100089A1 (en) | Methods and composition for induction of immune response | |
| AR110250A1 (es) | Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida | |
| RU2014101173A (ru) | Новые липидомиметики и их применение | |
| ES2894138T3 (es) | Composiciones de vacuna novedosas que comprenden oligonucleótidos inmunoestimulantes | |
| BR112016012435A8 (pt) | vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2 | |
| AR124747A1 (es) | Químico agrícola u hortícola, métodos para proteger cultivos agrícolas y control de plagas, y producto para proteger cultivos agrícolas y control de plagas |